1. Late Breaking Abstract (LBA-1): Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National C...

Since there is no mention of “non-cancer blood disorders”, I wanted to point out the late breaking abstract for oral Iptacopan in PNH. Data looks promising. This is the conclusion of the abstract PNH-Apply authors wrote: Conclusions: "In this Phase III trial in PNH patients with res...

The plenary paper of the trail from the European MCL network that demonstrated non inferiority of ibrutinib when compared with autologous transplant. The 2 Bite trials for 1. Myeloma with a GPRC5D target and 2. The CD20 bite for lymphoma after failure of CD19 Car T cells.

REMoDL-B - Improved OS with the addition of bortezomib to first like RCHOP in sequencing-defined ABC-DLBCL (and MHG although comparator was RCHOP, not REPOCH as many prefer in HGL). TRIANGLE - the ability to add Ibr to Nordic-style induction and 2y of maintenance in lieu of auto transplant consol...

1. TRIANGLE study – looked at adding ibrutinib to induction chemotherapy and whether using it in maintenance could allow for omission of ASCT. At this point, the study is too immature to say it is practice changing. We do not know if the early events are from high-risk patients that were resc...

Stephen Oh et al. Bone marrow fibrosis changes and clinical correlations, or lack thereof, from the SIMPLIFY-1 trial. (Saturday, 12/10/22 oral session). Commentary: Although a hallmark of the disease (barring some cases of pre-fibrotic primary myelofibrosis), the importance of bone marrow fibro...

For the second consecutive year, I attended ASH virtually. Now a veteran of such video experiences, I found the ASH home page very easy to navigate. I was grateful to avoid airline flights and the long walks between sessions but missed the random and serendipitous interactions with friends while rac...

I was asked by theMednet what I considered to be the "top 3" presentations from the 2022 ASH meeting, my thoughts on their impact, and what questions did these studies raise in my clinical practice? Since my practice focuses on the myeloproliferative neoplasms (MPN), I wasn’t certain whether ...